Lantheus shares barely moved, closing at $101.44 on August 5, up 0.3%. The latest filing offers a similarly calm headline: revenue rose 2.7% to $388.2 million in the three months ended June 30.

The quieter detail is that gross profit barely moved, up 0.4% to $241.9 million. Gross margin fell from 63.8% to 62.3%, so the additional sales carried less profit before operating expenses.

That did not stop operating income from rising 13.9% to $100.2 million. Research and development expense fell 16% to $38.2 million, the largest disclosed operating-cost change in the comparison. Net income still fell 4.7% to $75.0 million, and diluted EPS slipped to $1.11 from $1.12 despite a 4% reduction in diluted shares.

Management attributed the gross-profit increase to Neuraceq revenue after the Lantheus Biosciences acquisition, higher sales volume for PYLARIFY and DEFINITY, and more MK-6240 revenue for investigational use. The filing also shows rebate liabilities rising from $66.4 million at January 1 to $70.5 million at June 30, after $105.3 million of current-period provisions and $101.3 million of payments or credits.

The company’s own explanation is worth reading because it puts sales growth and rebate liabilities in the same passage:

"A roll forward of the amount of, and change in, accruals for rebate liabilities is summarized as follows: (in thousands) Rebates Balance at January 1, 2026 $ 66,448 Provision related to current period revenues 105,315 Payments or credits made during the period (101,299 ) Balance at June 30, 2026 $ 70,464 Gross Profit The increase in gross profit for the three months ended June 30, 2026, as compared to the prior year period, is primarily due to an increase in revenue from Neuraceq subsequent to the July 2025 acquisition of Lantheus Biosciences, increased PYLARIFY and DEFINITY sales volume and an increase in revenue from MK-6240 for investigational use."

10-Q, August 6, 2026

In plain English, the filing describes a business adding revenue from Neuraceq and volume from established products, while the gross-profit percentage moves the other way. The six-month discussion separately says a lower PYLARIFY net sales price weighed on gross profit more heavily than in the three-month comparison. Lantheus does not give a single quarter-specific explanation for the decline in net income.

Cash also fell to $593.3 million from $695.6 million a year earlier. Lantheus said lower average cash balances after the Evergreen and Lantheus Biosciences acquisitions reduced interest income in the six-month comparison. For the three-month period, other income increased by $1 million, helped by a $2.5 million gain on converting an installment note.

The company’s capital-needs language lists product pricing, revenue mix, commercialization costs, launch preparation, and acquisition integration. That sits alongside a stock valued at 29.7 times earnings, because the filing’s operating-profit improvement rests beside a thinner gross margin and a smaller cash balance.

Lantheus’s next quarterly report will add the missing comparison: whether PYLARIFY’s net sales price and consolidated gross margin changed again after this period.

More sales, higher operating income, thinner gross economics, and lower cash are all true at once.